Seer, Inc. (NASDAQ:SEER – Get Free Report) CFO David Horn sold 6,797 shares of the firm’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total transaction of $13,390.09. Following the sale, the chief financial officer owned 436,802 shares in the company, valued at $860,499.94. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Seer Stock Up 1.5%
SEER stock traded up $0.03 during trading on Friday, reaching $1.97. The company’s stock had a trading volume of 166,159 shares, compared to its average volume of 198,122. The company’s fifty day moving average is $2.17 and its 200-day moving average is $2.12. The company has a market capitalization of $109.91 million, a P/E ratio of -1.45 and a beta of 1.59. Seer, Inc. has a 1 year low of $1.62 and a 1 year high of $2.63.
Seer (NASDAQ:SEER – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The firm had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $4.00 million. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%. Seer has set its FY 2025 guidance at EPS. Analysts anticipate that Seer, Inc. will post -1.42 earnings per share for the current year.
Institutional Investors Weigh In On Seer
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
View Our Latest Analysis on SEER
About Seer
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Read More
- Five stocks we like better than Seer
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- The 3 Best Fintech Stocks to Buy Now
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
